docetaxel anhydrous has been researched along with Cystadenocarcinoma, Serous in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, B; He, L; Li, Y; Yuan, J | 1 |
| Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N | 1 |
| Kim, S; Kim, SW; Kim, YT; Lee, J; Li, LY; Nam, EJ | 1 |
| Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N | 1 |
| Leminen, A; Mäenpää, J | 1 |
| Carlson, MJ; Cohn, DE; Copeland, LJ; Fowler, JM; O'Malley, DM; Richardson, DL; Seamon, LG | 1 |
| Braun, M; Büttner, R; Fimmers, R; Friedrichs, N; Keyver-Paik, MD; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Sauerwald, A | 1 |
| Delle, U; Horvath, G; Levan, K; Olsson, B; Osterberg, L; Partheen, K; Sundfeldt, K | 1 |
| Dohi, S; Inoue, M; Kyo, S; Ohno, S; Ohno, Y; Soma, G; Sugiyama, H; Takakura, M | 1 |
| Arichi, N; Hiraoka, T; Honda, S; Igawa, M; Mitsui, Y; Shiina, H; Yasumoto, H | 1 |
| Chérel, M; Classe, JM; Collet, M; Dupré, PF; Gouard, S; Muller, M | 1 |
| Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T | 1 |
| Hirata, Y; Imanishi, K; Kaku, M; Kobayashi, A; Murao, S; Ohara, N; Seima, Y; Tomura, N; Yamasaki, M | 1 |
| Atkinson, T; Berkenblit, A; Cannistra, SA; Krasner, CN; Matulonis, UA; Mezzetti, L; Penson, RT; Roche, M; Seiden, MV | 1 |
| Hamada, K; Kakihara, Y; Kubota, K; Sawada, T; Tagaya, N | 1 |
| Aoki, D; Eguchi, F; Fujiwara, K; Jobo, T; Katsumata, N; Kitagawa, R; Kohno, I; Kuramoto, H; Nishimura, R; Noda, K; Nozawa, S; Sohda, Y; Susumu, N; Ueki, K; Ueki, M; Yamaguchi, S | 1 |
| Hirabayashi, K; Kono, I; Noda, K; Ogita, Y; Taguchi, T; Terajima, Y; Yakushiji, M | 1 |
1 review(s) available for docetaxel anhydrous and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Docetaxel; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoplasm Grading; Peritoneal Neoplasms; Prognosis; Survival Rate; Taxoids; Thoracic Surgery, Video-Assisted | 2017 |
5 trial(s) available for docetaxel anhydrous and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2016 |
Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2009 |
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids | 2004 |
Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids | 2005 |
[Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 1994 |
11 other study(ies) available for docetaxel anhydrous and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety; Survival Rate; Young Adult | 2019 |
Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Intraperitoneal; Middle Aged; Outpatients; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Changes in Ki-67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Cell Proliferation; Clinical Trials, Phase II as Topic; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Chromosome Mapping; Comparative Genomic Hybridization; Cystadenocarcinoma, Serous; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Gene Expression Profiling; Humans; Ovarian Neoplasms; Pilot Projects; Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2010 |
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Topics: Adjuvants, Immunologic; Biomarkers, Tumor; CA-125 Antigen; Cancer Vaccines; Carboplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Female; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy, Active; Membrane Proteins; Middle Aged; Omentum; Ovarian Neoplasms; Paclitaxel; Peptide Fragments; Peritoneal Neoplasms; Taxoids; Tumor Burden; Vaccines, Subunit; WT1 Proteins | 2011 |
A case of primary retroperitoneal serous adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Docetaxel; Female; Humans; Retroperitoneal Neoplasms; Taxoids | 2011 |
The cytotoxic effect of combined hyperthermia and taxane chemotherapy on ovarian cancer cells: results of an in vitro study.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cold Temperature; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Female; Humans; Lethal Dose 50; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2012 |
[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Taxoids | 2003 |
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mesentery; Neoplasm Recurrence, Local; Pelvic Neoplasms; Retroperitoneal Neoplasms; Taxoids; Tomography, X-Ray Computed | 2004 |
[Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Humans; Middle Aged; Preoperative Care; Taxoids | 2004 |